William Blair Issues Positive Outlook for APLS Earnings

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Stock analysts at William Blair increased their Q2 2026 earnings per share estimates for shares of Apellis Pharmaceuticals in a research report issued to clients and investors on Tuesday, April 1st. William Blair analyst L. Hanbury-Brown now forecasts that the company will post earnings of $0.20 per share for the quarter, up from their prior estimate of $0.18. The consensus estimate for Apellis Pharmaceuticals' current full-year earnings is ($1.70) per share. William Blair also issued estimates for Apellis Pharmaceuticals' Q3 2026 earnings at $0.33 EPS, Q4 2026 earnings at $0.47 EPS and FY2026 earnings at $1.01 EPS.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last posted its quarterly earnings results on Friday, February 28th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.08. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The firm had revenue of $212.50 million for the quarter, compared to analyst estimates of $197.92 million. During the same period in the previous year, the firm earned ($0.73) earnings per share. Apellis Pharmaceuticals's quarterly revenue was up 45.2% on a year-over-year basis.

APLS has been the subject of a number of other research reports. Scotiabank upped their target price on Apellis Pharmaceuticals from $30.00 to $31.00 and gave the stock a "sector perform" rating in a research report on Wednesday, April 2nd. HC Wainwright reissued a "buy" rating and set a $57.00 price target on shares of Apellis Pharmaceuticals in a research report on Monday, March 3rd. JPMorgan Chase & Co. boosted their price target on Apellis Pharmaceuticals from $50.00 to $54.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 4th. Royal Bank of Canada dropped their price objective on Apellis Pharmaceuticals from $26.00 to $25.00 and set a "sector perform" rating on the stock in a research note on Monday, March 3rd. Finally, Wedbush decreased their target price on shares of Apellis Pharmaceuticals from $30.00 to $29.00 and set a "neutral" rating for the company in a research note on Monday, March 3rd. Eight analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $45.59.

Apellis Pharmaceuticals Stock Down 3.1 %

Shares of NASDAQ APLS traded down $0.61 during trading hours on Thursday, hitting $19.20. The stock had a trading volume of 679,548 shares, compared to its average volume of 2,095,079. Apellis Pharmaceuticals has a 52 week low of $18.21 and a 52 week high of $57.85. The firm's 50-day moving average price is $26.02 and its two-hundred day moving average price is $28.84. The company has a market capitalization of $2.41 billion, a P/E ratio of -9.41 and a beta of 0.85. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36.

Institutional Trading of Apellis Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in APLS. EverSource Wealth Advisors LLC grew its position in Apellis Pharmaceuticals by 2,707.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company's stock valued at $25,000 after buying an additional 758 shares during the period. Signaturefd LLC lifted its position in Apellis Pharmaceuticals by 357.2% in the fourth quarter. Signaturefd LLC now owns 1,175 shares of the company's stock valued at $37,000 after purchasing an additional 918 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Apellis Pharmaceuticals in the 4th quarter worth approximately $83,000. US Bancorp DE boosted its stake in shares of Apellis Pharmaceuticals by 70.0% during the 4th quarter. US Bancorp DE now owns 3,223 shares of the company's stock valued at $103,000 after purchasing an additional 1,327 shares in the last quarter. Finally, Covestor Ltd raised its stake in Apellis Pharmaceuticals by 1,819.2% in the fourth quarter. Covestor Ltd now owns 3,992 shares of the company's stock worth $127,000 after buying an additional 3,784 shares in the last quarter. 96.29% of the stock is owned by institutional investors.

Insider Transactions at Apellis Pharmaceuticals

In other news, General Counsel David O. Watson sold 5,569 shares of the business's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $25.10, for a total transaction of $139,781.90. Following the sale, the general counsel now directly owns 138,730 shares in the company, valued at approximately $3,482,123. The trade was a 3.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Cedric Francois sold 2,824 shares of Apellis Pharmaceuticals stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $29.52, for a total transaction of $83,364.48. Following the transaction, the chief executive officer now owns 415,695 shares in the company, valued at approximately $12,271,316.40. This trade represents a 0.67 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 63,238 shares of company stock valued at $1,857,510. Corporate insiders own 6.80% of the company's stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).